Format

Send to

Choose Destination
J Surg Oncol. 2016 Oct;114(5):587-596. doi: 10.1002/jso.24375. Epub 2016 Jul 21.

Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?

Author information

1
Division of Hematology/Oncology, University of California San Francisco, San Francisco, California.
2
Department of Surgery, University of California San Francisco, San Francisco, California. eric.nakakura@ucsf.edu.
3
Department of Radiology, University of California San Francisco, San Francisco, California.
4
Department of Pathology, University of California San Francisco, San Francisco, California.
5
Department of Surgery, University of California San Francisco, San Francisco, California.
6
Division of Hematology/Oncology, University of California San Francisco, San Francisco, California. andrewko@medicine.ucsf.edu.

Abstract

BACKGROUND:

No consensus exists regarding the optimal neoadjuvant treatment paradigm for patients with borderline resectable pancreatic cancer (BRPC), including the respective roles of chemotherapy and radiation.

METHODS:

We performed a retrospective analysis, including detailed pathologic and radiologic review, of pancreatic cancer patients undergoing FOLFIRINOX, with or without radiation therapy (RT), prior to surgical resection at a high-volume academic center over a 4-year period.

RESULTS:

Of 26 patients meeting inclusion criteria, 22 (84.6%) received FOLFIRINOX alone without RT (median number of treatment cycles = 9). The majority of patients met formal radiographic criteria for BRPC, with the superior mesenteric vein representing the most common vessel involved. R0 resection rate was 90.9%, with 12 patients (54.5%) requiring vascular reconstruction. Treatment response was classified as moderate or marked in 16 patients (72.7%) according to the College of American Pathologists grading system. Estimated median disease-free and overall survival rates are 22.6 months and not reached (NR), respectively.

CONCLUSIONS:

This is one of the largest series to describe the use of neoadjuvant FOLFIRINOX, without radiation therapy, in patients with BRPC undergoing surgical resection. Given the high R0 resection rates and favorable clinical outcomes with chemotherapy alone, this strategy should be further assessed in prospective study design. J. Surg. Oncol. 2016;114:587-596. © 2016 Wiley Periodicals, Inc.

KEYWORDS:

FOLFIRINOX; borderline resectable; neoadjuvant; pancreatic cancer

PMID:
27444658
DOI:
10.1002/jso.24375
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center